Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).
Boye KS, Poon JL, Landó LF, Sapin H, Huh R, Wang M, Williamson S, Patel H. Boye KS, et al. Diabetes Ther. 2024 Sep;15(9):2039-2059. doi: 10.1007/s13300-024-01620-8. Epub 2024 Jul 15. Diabetes Ther. 2024. PMID: 39008236 Free PMC article.
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
Barrett A, Boye KS, García-Pérez LE, Giorgino F, Guerci B, Füchtenbusch M, Yu M, Sapin H, Dib A, Heitmann E, Federici MO, Lebrec J. Barrett A, et al. Among authors: boye ks. J Med Econ. 2024 Jan-Dec;27(1):866-879. doi: 10.1080/13696998.2024.2367919. Epub 2024 Jul 4. J Med Econ. 2024. PMID: 38963346 Free article.
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS, Lebrec J, Dib A, Heitmann E, Federici MO, Yu M, Sapin H, Barrett A, Guerci B, Giorgino F, Füchtenbusch M, García-Pérez LE. Boye KS, et al. Diabetes Obes Metab. 2023 Dec;25(12):3453-3464. doi: 10.1111/dom.15145. Epub 2023 Sep 15. Diabetes Obes Metab. 2023. PMID: 37712754
137 results